Wells Fargo & Company Myovant Sciences Ltd. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$24.03 - $27.02 $351,727 - $395,491	-14,637 Reduced 70.76%	6,048 $163,000
Q3 2022 Nov 14, 2022	SELL	$11.6 - $20.44 $26,250 - $46,255	-2,263 Reduced 9.86%	20,685 $371,000
Q2 2022 Aug 12, 2022	SELL	$7.78 - $14.69 $17,147 - $32,376	-2,204 Reduced 8.76%	22,948 $285,000
Q1 2022 May 16, 2022	SELL	$11.38 - $16.4 $18,424 - $26,551	-1,619 Reduced 6.05%	25,152 $335,000
Q4 2021 Feb 14, 2022	SELL	$14.31 - $23.87 $34,272 - $57,168	-2,395 Reduced 8.21%	26,771 $417,000
Q3 2021 Nov 15, 2021	SELL	$18.94 - $26.99 $24,962 - $35,572	-1,318 Reduced 4.32%	29,166 $654,000
Q2 2021 Aug 16, 2021	SELL	$17.07 - $24.56 $9,678 - $13,925	-567 Reduced 1.83%	30,484 $694,000
Q1 2021 May 13, 2021	BUY	$20.46 - $25.18 $152,222 - $187,339	7,440 Added 31.51%	31,051 $639,000
Q4 2020 Feb 09, 2021	BUY	$13.8 - $27.62 $127,387 - $254,960	9,231 Added 64.19%	23,611 $652,000
Q3 2020 Nov 05, 2020	SELL	$14.05 - $22.6 $147,623 - $237,458	-10,507 Reduced 42.22%	14,380 $202,000
Q2 2020 Aug 13, 2020	BUY	$7.34 - $20.84 $120,060 - $340,879	16,357 Added 191.76%	24,887 $513,000
Q1 2020 May 14, 2020	BUY	$6.55 - $14.76 $55,871 - $125,902	8,530 New	8,530 $64,000

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.